{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:31:16Z","timestamp":1794475876453,"version":"4.9.1"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5-K08CA267062-04"],"award-info":[{"award-number":["5-K08CA267062-04"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcpo.2026.100784","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:27:53Z","timestamp":1784615273000},"page":"100784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Financial factors shaping treatment decisions in oncology: A systematic review"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0536-9101","authenticated-orcid":false,"given":"Ebunoluwa J.","family":"Olunuga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anagh","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Kurnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cantrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah R.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jcpo.2026.100784_bib1","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.jcpo.2026.100784_bib2","first-page":"153","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.jcpo.2026.100784_bib3","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/tbm\/ibab091","article-title":"Financial toxicity in cancer care: origins, impact, and solutions","volume":"11","author":"Abrams","year":"2021","journal-title":"Transl. Behav. Med."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JOP.2013.001322","article-title":"Impact of financial burden of cancer on survivors' quality of life","volume":"10","author":"Fenn","year":"2014","journal-title":"J. Oncol. Pract."},{"issue":"2","key":"10.1016\/j.jcpo.2026.100784_bib5","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1200\/JOP.2017.027136","article-title":"Relationship Between Objective Financial Burden and the Health-Related Quality of Life and Mental Health of Patients With Cancer","volume":"14","author":"Park","year":"2018","journal-title":"J. Oncol. Pract."},{"issue":"9","key":"10.1016\/j.jcpo.2026.100784_bib6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/OP-24-00528","article-title":"Impact of financial toxicity on treatment adherence and quality of life in pancreatic cancer","volume":"21","author":"Schleimer","year":"2025","journal-title":"JCO Oncol. Pract."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_bib7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_bib8","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.juro.2017.10.049","article-title":"Financial Toxicity among Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life","volume":"199","author":"Casilla-Lennon","year":"2018","journal-title":"J. Urol."},{"key":"10.1016\/j.jcpo.2026.100784_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104140","article-title":"Interventions for financial toxicity among cancer survivors: A scoping review","volume":"192","author":"Yuan","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100784_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.amepre.2020.02.016","article-title":"Financial hardship, healthcare utilization, and health among U.S. Cancer Survivors","volume":"59","author":"Zheng","year":"2020","journal-title":"Am. J. Prev. Med."},{"issue":"9","key":"10.1016\/j.jcpo.2026.100784_bib11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev. Esp. Cardiol. (Engl. Ed. )"},{"key":"10.1016\/j.jcpo.2026.100784_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jcpo.2026.100784_bib14","doi-asserted-by":"crossref","unstructured":"Sterne J.A.C., Hern\u00e1n M.A., Reeves B.C., et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj-Brit Med J. Oct 12 2016;355doi:ARTN i4919 10.1136\/bmj.i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"10.1016\/j.jcpo.2026.100784_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2020.08.080","article-title":"Promotional payments made to urologists by the pharmaceutical industry and prescribing patterns for targeted therapies","volume":"148","author":"Hollenbeck","year":"2021","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.jcpo.2026.100784_bib16","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/jamainternmed.2018.0776","article-title":"Pharmaceutical industry payments and oncologists' selection of targeted cancer therapies in medicare beneficiaries","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100784_bib17","first-page":"7","article-title":"Factors influencing hematologists-oncologists\u2019 prescription of chemotherapy drugs in cancer treatment in Iran: an interview questionnaire study","volume":"13","author":"Abolfazli","year":"2017","journal-title":"Iran. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_bib18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1634\/theoncologist.2018-0423","article-title":"Evaluating the strength of the association between industry payments and prescribing practices in oncology","volume":"24","author":"Mitchell","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jcpo.2026.100784_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2021.10.042","article-title":"Promotional payments to medical oncologists and urologists and prescriptions for abiraterone and Enzalutamide","volume":"161","author":"Lai","year":"2022","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.jcpo.2026.100784_bib20","doi-asserted-by":"crossref","first-page":"e6s","DOI":"10.1200\/JOP.2012.000539","article-title":"Impact of payment reform on chemotherapy at the end of life","volume":"8","author":"Colla","year":"2012","journal-title":"J. Oncol. Pract."},{"issue":"34","key":"10.1016\/j.jcpo.2026.100784_bib21","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1200\/JCO.20.00890","article-title":"Association between a national insurer's pay-for-performance program for oncology and changes in prescribing of evidence-based cancer drugs and spending","volume":"38","author":"Bekelman","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10754-012-9117-y","article-title":"Physician response to financial incentives when choosing drugs to treat breast cancer","volume":"12","author":"Epstein","year":"2012","journal-title":"Int. J. Health Care Financ. Econ."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_bib23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1200\/JCO.2012.43.6063","article-title":"Medical oncologists' perceptions of financial incentives in cancer care","volume":"31","author":"Malin","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_bib24","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1200\/JOP.2015.007344","article-title":"Are small reimbursement changes enough to change cancer care? Reimbursement variation in prostate cancer treatment","volume":"12","author":"Ellis","year":"2016","journal-title":"J. Oncol. Pract."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_bib25","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1377\/hlthaff.2018.05083","article-title":"An Insurer's Program To Incentivize Generic Oncology Drugs Did Not Alter Treatment Patterns Or Spending On Care","volume":"38","author":"Yasaitis","year":"2019","journal-title":"Health Aff. (Millwood)"},{"issue":"3","key":"10.1016\/j.jcpo.2026.100784_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40259-021-00479-6","article-title":"Physician understanding and willingness to prescribe biosimilars: findings from a US National Survey","volume":"35","author":"Kolbe","year":"2021","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100784_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ph10010019","article-title":"Barriers to the access of bevacizumab in patients with solid tumors and the potential impact of biosimilars: a physician survey","volume":"10","author":"Monk","year":"2017","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.jcpo.2026.100784_bib28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/GO.20.00649","article-title":"Biosimilar use in breast cancer treatment: a national survey of Brazilian oncologists' opinions, practices, and concerns","author":"Resende","year":"2021","journal-title":"JCO Glob. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100784_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-022-06615-2","article-title":"Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients","volume":"194","author":"Papautsky","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jcpo.2026.100784_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2019.100195","article-title":"The tip of the iceberg? Budget restrictions and patient perspectives on cancer drug costs: An international survey in 29 hospitals and 56 patient organizations","volume":"21","author":"van Harten","year":"2019","journal-title":"J. Cancer Policy"},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_bib31","first-page":"2902","article-title":"Recommending Unfunded Innovative Cancer Therapies: Ethical vs. Clinical Perspectives among Oncologists on a Public Healthcare System-A Mixed-Methods Study","volume":"28","author":"Bashkin","year":"2021","journal-title":"Curr"},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/23294515.2022.2110963","article-title":"Physicians' Perspectives on Ethical Issues Regarding Expensive Anti-Cancer Treatments: A Qualitative Study","volume":"13","author":"Bomhof","year":"2022","journal-title":"AJOB Empir. Bioeth."},{"issue":"3","key":"10.1016\/j.jcpo.2026.100784_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JOP.2011.000337","article-title":"Less than ideal: how oncologists practice with limited drug access","volume":"8","author":"Chan","year":"2012","journal-title":"J. Oncol. Pract."},{"issue":"13","key":"10.1016\/j.jcpo.2026.100784_bib34","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ejca.2007.05.017","article-title":"Cost issues in new disease-modifying treatments for advanced cancer: in-depth interviews with physicians","volume":"43","author":"de Kort","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_bib35","first-page":"530","article-title":"Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey","volume":"7","author":"Baer Ii","year":"2014","journal-title":"Pharm. (Basel)"},{"issue":"10","key":"10.1016\/j.jcpo.2026.100784_bib36","doi-asserted-by":"crossref","first-page":"e1232","DOI":"10.1200\/JOP.19.00781","article-title":"Treatment Decision Drivers in Stage III Non-Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States","volume":"16","author":"Cotarla","year":"2020","journal-title":"JCO Oncol. Pract."},{"issue":"2","key":"10.1016\/j.jcpo.2026.100784_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/1467-9566.12830","article-title":"Treat them into the grave': cancer physicians' attitudes towards the use of high-cost cancer medicines at the end of life","volume":"41","author":"Wiersma","year":"2019","journal-title":"Sociol. Health Illn."},{"issue":"07","key":"10.1016\/j.jcpo.2026.100784_bib38","article-title":"Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA","volume":"07","author":"Ribbands","year":"2023","journal-title":"Fut. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100784_bib39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1080\/13696998.2022.2062951","article-title":"The relationship between cost and the recommendation, refusal, and discontinuation of treatment for chronic myeloid leukemia and multiple myeloma in Japan: a cross-sectional exploratory survey","volume":"25","author":"Munakata","year":"2022","journal-title":"J. Med. Econ."},{"issue":"2","key":"10.1016\/j.jcpo.2026.100784_bib40","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1634\/theoncologist.11-2-90","article-title":"Do oncologists believe new cancer drugs offer good value?","volume":"11","author":"Nadler","year":"2006","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.jcpo.2026.100784_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-062104","article-title":"Patients' and oncologists' perceptions towards the discussion on high-cost innovative cancer therapies: findings from a qualitative study","volume":"12","author":"Bashkin","year":"2022","journal-title":"BMJ Open."},{"issue":"8","key":"10.1016\/j.jcpo.2026.100784_bib42","first-page":"4835","article-title":"Defining the clinician's role in mitigating financial toxicity: an exploratory study","volume":"29","author":"Ragavan","year":"2021","journal-title":"Support. Care Cancer"},{"issue":"3","key":"10.1016\/j.jcpo.2026.100784_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.2015.007401","article-title":"Physician Experience and Attitudes Toward Addressing the Cost of Cancer Care","volume":"12","author":"Altomare","year":"2016","journal-title":"J. Oncol. Pract."},{"issue":"10","key":"10.1016\/j.jcpo.2026.100784_bib44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2217\/imt-2020-0118","article-title":"Perceptions of community hematologists\/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"issue":"27","key":"10.1016\/j.jcpo.2026.100784_bib45","first-page":"45","article-title":"Awareness, understanding, attitude and barriers toward prescribing modern cancer immunotherapies in the Arabian Gulf countries","volume":"1","author":"HO","year":"2018","journal-title":"Gulf J. Oncol."},{"issue":"9","key":"10.1016\/j.jcpo.2026.100784_bib46","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000475759","article-title":"The role of physicians in rationing cancer care. Attitudes of German Oncologists","volume":"40","author":"Fernau","year":"2017","journal-title":"Oncol. Res. Treat."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100784_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jgo.2019.03.010","article-title":"Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study","volume":"11","author":"Boque","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.jcpo.2026.100784_bib48","article-title":"Perspectives toward biosimilars among oncologists: a Malaysian survey","author":"Chong","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jcpo.2026.100784_bib49","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2147\/PPA.S299399","article-title":"Differences in lung cancer treatment preferences among oncologists, patients and family members: a semi-structured qualitative study in China","volume":"15","author":"He","year":"2021","journal-title":"Patient Prefer. Adherence"},{"issue":"11","key":"10.1016\/j.jcpo.2026.100784_bib50","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1054\/bjoc.2001.1817","article-title":"A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom","volume":"84","author":"Sambrook","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.jcpo.2026.100784_bib51","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JGO.19.00341","article-title":"Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets","author":"Patel","year":"2020","journal-title":"JCO Glob. Oncol."},{"issue":"3","key":"10.1016\/j.jcpo.2026.100784_bib52","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/jha2.505","article-title":"Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions","volume":"3","author":"Major","year":"2022","journal-title":"eJHaem"},{"issue":"18","key":"10.1016\/j.jcpo.2026.100784_bib53","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1002\/cncr.31532","article-title":"Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer","volume":"124","author":"Jagsi","year":"2018","journal-title":"Cancer"},{"issue":"37","key":"10.1016\/j.jcpo.2026.100784_bib54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/EDBK_175533","article-title":"Perspectives on the use of clinical pathways in oncology care","author":"Chiang","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"3","key":"10.1016\/j.jcpo.2026.100784_bib55","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JOP.2015.009134","article-title":"American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology","volume":"12","author":"Zon","year":"2016","journal-title":"J. Oncol. Pract."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_bib56","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.jcpo.2026.100784_bib57","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2015-0026","article-title":"Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients","volume":"20","author":"Delgado-Guay","year":"2015","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.jcpo.2026.100784_bib58","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/M20-5665","article-title":"Are financial payments from the pharmaceutical industry associated with physician prescribing?: A systematic review","volume":"174","author":"Mitchell","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_bib59","first-page":"303","article-title":"Physician behavior impact when revenue shifted from drugs to services","volume":"20","author":"Feinberg","year":"2014","journal-title":"Am. J. Manag. Care"},{"issue":"30","key":"10.1016\/j.jcpo.2026.100784_bib60","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.2217\/fon-2021-0618","article-title":"Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA","volume":"17","author":"Shelbaya","year":"2021","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_bib61","first-page":"S91","article-title":"Uptake of oncology biosimilars: managed care strategies to improve value-based care systems","volume":"28","author":"Liu","year":"2022","journal-title":"Am. J. Manag. Care"},{"issue":"7","key":"10.1016\/j.jcpo.2026.100784_bib62","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/bmt.2010.225","article-title":"Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment","volume":"46","author":"Shafey","year":"2011","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_bib63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/jmahp12040031","article-title":"Managing pharmaceutical costs in health systems: a review of affordability, accessibility and sustainability strategies","volume":"12","author":"Ntais","year":"2024","journal-title":"J. Mark. Access. Health Policy"},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_bib64","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamainternmed.2020.8441","article-title":"Assessment of coverage in england of cancer drugs qualifying for US Food and Drug Administration Accelerated Approval","volume":"181","author":"Cherla","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"11","key":"10.1016\/j.jcpo.2026.100784_bib65","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1377\/hlthaff.2019.01804","article-title":"Getting the price right: how some countries control spending in a fee-for-service system","volume":"39","author":"Gusmano","year":"2020","journal-title":"Health Aff. (Millwood)"},{"issue":"2","key":"10.1016\/j.jcpo.2026.100784_bib66","first-page":"126","article-title":"Characterizing health plan price estimator tools: findings from a national survey","volume":"22","author":"Higgins","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.jcpo.2026.100784_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpopen.2026.100163","article-title":"Price transparency & out-of-pocket payments for medications: Implications of associated delivery fees in the United States","volume":"10","author":"Kaye","year":"2026","journal-title":"Health Policy Open."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102992","article-title":"ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer","volume":"9","author":"Carrera","year":"2024","journal-title":"ESMO Open."},{"issue":"20","key":"10.1016\/j.jcpo.2026.100784_bib69","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/cncr.28814","article-title":"The development of a financial toxicity patient-reported outcome in cancer: The COST measure","volume":"120","author":"de Souza","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jcpo.2026.100784_bib70","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cncr.30369","article-title":"Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)","volume":"123","author":"de Souza","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jcpo.2026.100784_bib71","first-page":"3219","article-title":"A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system","volume":"29","author":"Riva","year":"2021","journal-title":"Support. Care Cancer"},{"issue":"10","key":"10.1016\/j.jcpo.2026.100784_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049128","article-title":"Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system","volume":"11","author":"Riva","year":"2021","journal-title":"BMJ Open."},{"key":"10.1016\/j.jcpo.2026.100784_bib73","article-title":"Development and Validation of Subjective Financial Distress Questionnaire (SFDQ): a patient reported outcome measure for assessment of financial toxicity among radiation oncology patients","volume":"11","author":"Dar","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jcpo.2026.100784_bib74","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/JMDH.S300061","article-title":"Decision-making in multidisciplinary tumor boards in breast cancer care - an observational study","volume":"14","author":"Schellenberger","year":"2021","journal-title":"J. Multidiscip. Healthc."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_bib75","doi-asserted-by":"crossref","first-page":"164","DOI":"10.6004\/jnccn.2025.7010","article-title":"The Financial Toxicity Tumor Board: 5-Year Update on Practice and a Guide to Implementation","volume":"23","author":"Knight","year":"2025","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100784_bib76","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1186\/s12913-022-08112-0","article-title":"Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review","volume":"22","author":"Walraven","year":"2022","journal-title":"BMC Health Serv. Res."},{"issue":"9","key":"10.1016\/j.jcpo.2026.100784_bib77","first-page":"1162","article-title":"HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales","volume":"26","author":"Thokala","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"27","key":"10.1016\/j.jcpo.2026.100784_fur1","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1200\/JCO.2010.29.1625","article-title":"Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs","volume":"28","author":"Berry","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jcpo.2026.100784_fur2","first-page":"99","article-title":"Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs","volume":"5","author":"Daroudi","year":"2015","journal-title":"Int"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100784_fur3","first-page":"35","article-title":"Factors influencing oncologists' prescribing hormonal therapy in women with breast cancer: a qualitative study in Cordoba, Argentina","volume":"18","author":"Eraso","year":"2019","journal-title":"Intern"},{"issue":"12","key":"10.1016\/j.jcpo.2026.100784_fur4","first-page":"5709","article-title":"Cost health literacy as a physician skill-set: the relationship between oncologist reported knowledge and engagement with patients on financial toxicity","volume":"28","author":"Fischer","year":"2020","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.jcpo.2026.100784_fur5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.vhri.2019.03.005","article-title":"What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria","volume":"19","author":"Iskrov","year":"2019","journal-title":"Value Health Reg. Issues"},{"issue":"2","key":"10.1016\/j.jcpo.2026.100784_fur6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1377\/hlthaff.25.2.437","article-title":"Does reimbursement influence chemotherapy treatment for cancer patients?","volume":"25","author":"Jacobson","year":"2006","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.jcpo.2026.100784_fur7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/PPA.S241340","article-title":"Qualitative Study of Factors Affecting Patient, Caregiver and Physician Preferences for Treatment of Myeloma and Indolent Lymphoma","volume":"14","author":"Jen","year":"2020","journal-title":"Patient Prefer. Adherence"},{"issue":"2","key":"10.1016\/j.jcpo.2026.100784_fur8","first-page":"19","article-title":"Current Situation of Diagnosis and Treatment of HER2-Positive Metastatic Breast Cancer Patients in China: A Nationwide Cross-Sectional Survey of Doctors","volume":"13","author":"Jiang","year":"2023","journal-title":"J"},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_fur9","first-page":"1","article-title":"Bortezomib prescription pattern for the treatment of multiple myeloma by hematologists in Nigeria","author":"Korubo","year":"2018","journal-title":"J"},{"issue":"10","key":"10.1016\/j.jcpo.2026.100784_fur10","first-page":"2832","article-title":"Impact of anticancer drugs price cut on physician's prescription choices on first-line chemotherapy regimens and health expenditure for advanced non-small cell lung cancer in China","volume":"8","author":"Li","year":"2016","journal-title":"J"},{"issue":"2","key":"10.1016\/j.jcpo.2026.100784_fur11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0090-4295(96)00434-7","article-title":"Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs","volume":"49","author":"Matchar","year":"1997","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.jcpo.2026.100784_fur12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3747\/co.v16i4.375","article-title":"Perceptions of health care providers concerning patient and health care provider strategies to limit out-of-pocket costs for cancer care","volume":"16","author":"Mathews","year":"2009","journal-title":"Curr. Oncol."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_fur13","first-page":"280","article-title":"Oncologist Support for Consolidated Payments for Cancer Care Management in the United States","volume":"9","author":"Narayanan","year":"2016","journal-title":"Am"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100784_fur14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1377\/hlthaff.2009.0077","article-title":"Cancer therapy costs influence treatment: a national survey of oncologists","volume":"29","author":"Neumann","year":"2010","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.jcpo.2026.100784_fur15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jcpo.2016.09.008","article-title":"Trends in Antineoplastic Receipt after Medicare Payment Reform: Implications for Future Oncology Payment Design","volume":"17","author":"Parsons","year":"2018","journal-title":"J. Cancer Policy"},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_fur16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1464-410X.2011.10886.x","article-title":"Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities","volume":"110","author":"Payne","year":"2012","journal-title":"BJU Int."},{"issue":"6","key":"10.1016\/j.jcpo.2026.100784_fur17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2967\/jnumed.109.073155","article-title":"Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of US Medical Oncologists and Hematologists","volume":"51","author":"Schaefer","year":"2010","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100784_fur18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2967\/jnumed.110.085589","article-title":"Radioimmunotherapy in non-Hodgkin lymphoma: Opinions of nuclear medicine physicians and radiation oncologists","volume":"52","author":"Schaefer","year":"2011","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.jcpo.2026.100784_fur19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1200\/JCO.2006.09.2437","article-title":"Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey","volume":"25","author":"Schrag","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jcpo.2026.100784_fur20","doi-asserted-by":"crossref","first-page":"e1424","DOI":"10.1200\/OP.21.00042","article-title":"Are cost-of-care conversations best practice? A qualitative study of oncologists' attitudes and practice","volume":"17","author":"Scott","year":"2021","journal-title":"JCO Oncol. Pract."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:08:49Z","timestamp":1794474529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":96,"alternative-id":["S2213538326000858"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100784","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Financial factors shaping treatment decisions in oncology: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100784"}}